Participate in a Clinical Trial

Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing and treating T1D. There are many opportunities in the Greater New York Metro area and virtually to participate in a T1D clinical trial close to home. See below for active opportunities!

Breakthrough T1D has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting breakthrought1d.org/impact/research/clinical-trials today!

FEATURED T1D STUDIES IN
GREATER NEW YORK

CNP-103

The purpose of this study is to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103, an investigational treatment for T1D. Participants will receive either CNP-103 or a placebo through an intravenous (IV) infusion on Day 1, Day 8, and Day 90. A participant will be involved in the study for approximately 208 days, which includes screening (up to 28 days), active study participation (approximately 90 days), and a follow-up period.

Who is eligible:

• Who are 12-35 years old
• Diagnosed with Stage 3 type 1 diabetes within the past 180 days (based on ADA guidelines)

CHORD1

The purpose of this study is to investigate why individuals with type 1 diabetes remain at increased risk for heart disease and stroke, even after the reduction of their “bad” LDL-cholesterol.

Who is eligible:

• Who are ≥ 18 years old
• Who have been diagnosed with type 1 diabetes
• Who also have an LDL-cholesterol ≥ 100mg/dL

CATT1 

The purpose of this study is to investigate if the study drug, cadisegliatin, as adjunctive therapy with insulin, will reduce the incidence of hypoglycemia in participants with Type 1 diabetes. 

Who is eligible:

• Who are ≥ 18 years old
• Diagnosed with T1D with minimum 5 years since diagnosis
• Had at least 1 hypoglycemic event of Level 2 or 3 within last 2 months
• HbA1c value <9.5%
• Currently on CSII (continuous subcutaneous insulin infusion) or MDI (multiple daily injections) for at least 6 months prior to screening
• Have used a CGM (continuous glucose monitor) device for at least 3 months prior to screening

DESIGNATE

The goal of this study is to see how the experimental study drug, siplizumab, can block or weaken the cells that attack beta cells in the pancreas. This would allow the beta cells to continue to function and produce insulin.

Who is eligible:

• Between the ages of 18 and 45
• Have been diagnosed with type 1 diabetes within the last 18 months
• Are in good general health

DESIGNATE is active, but not currently enrolling participants

DIAGNODE-3

DIAGNODE-3 is a Breakthrough T1D-funded phase 3 clinical trial of the disease-modifying therapy Diamyd®. The goal is to preserve as many healthy beta cells as possible to maintain the body’s own insulin production.

Who is eligible:

• Between the ages of 12-28
• Have been diagnosed with stage 3 type 1 diabetes within the last 6 months
• Tested positive for a specific genetic marker (HLA DR3-DQ2)

View our Breakthrough T1D article covering this study HERE!

JAKPOT T1D

TrialNet is testing two different Janus kinase (JAK) inhibitors to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).

Who is eligible:

• Age 12-35
• Newly diagnosed with T1D (in past 3 months)
• Up to date on required vaccines (including the flu vaccine when it is available)
• Not pregnant, breastfeeding or planning to become pregnant while in the study
• AND have:
  • One or more diabetes-related autoantibodies
  • Hemoglobin A1C below 10%
  • C-peptide detectable during a mixed-meal tolerance test (MMTT)

Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease 

This Phase 3 clinical trial aims to evaluate whether the SGLT2 inhibitor sotagliflozin (SOTA) can safely prevent or slow kidney function decline in people with T1D and diabetic kidney disease (DKD), using a comprehensive DKA prevention strategy. Over three years, the study will compare kidney outcomes between participants receiving SOTA and those receiving a placebo, with the goal of generating data to support potential FDA approval.  

Who is eligible:

• Person with T1D ages 18-75 years old, continuously treated with insulin within one year from diagnosis.
• Duration of T1D ≥ 8 years;
• eGFR based on serum creatinine and cystatin C between 20 and 60 ml/min/1.73 m2 at screening
• First morning void urinary albumin/creatinine ratio (UACR) ≥200 mg/g at screening
• HbA1c \<10% at screening

THE PROMISE STUDY 

Is your family expecting? Join Mount Sinai (NYC) in The Promise Study.

Who is eligible:

• Are you pregnant with type 1 diabetes?
• Are you an expectant father with type 1 diabetes?
• Are you an expectant parent with a child who has type 1 diabetes?

TRIALNET

This study is screening relatives of type 1 diabetes for the antibodies associated with a higher risk of developing type 1 diabetes. Autoantibodies are a sign that the immune system may be attacking the insulin-producing cells in the pancreas.

Who is eligible:

• People 2 years 6 months of age to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes.
• People 2 years 6 months of age to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandchild with type 1 diabetes.

Time Commitment:

One-time blood test: Capillary (finger-prick) or Venipuncture (blood draw). If tested positive, followed up annually or semi-annually until progression to Stage 3 T1D

Virtual Studies

T1DAL Study

Are you a teen with T1D? Do you want to learn how to live a healthier lifestyle? Consider joining TIDAL!

T1DAL stands for Type 1 Diabetes Adolescents for healthier Lifestyles. T1DAL was designed to support teens in living their healthiest and happiest lives with T1D.

This is a virtual, group-based program led by Brown University. You’ll be invited to attend one 60-minute session per week for about 4 months and a few individual check-in calls with a trained study staff member.

Interested? Fill out the interest form here: T1DAL Study.

If you have any questions, please contact our Greater New York Metro Chapter Clinical Trials Education Volunteer, Alecia Wesner.

Updated: July 14, 2025